Reuters |
AstraZeneca builds pipeline with $232 million Synairgen asthma deal
Reuters AstraZeneca plans to start a mid-stage Phase IIa study with the drug in early 2015 in patients with severe asthma, building on results from an initial Phase lla trial in a broad asthma population. Severe asthma is a growing focus for major drugmakers … Synairgen shares soar on AstraZeneca asthma deal AstraZeneca licenses rights to Synairgen asthma drug |
View full post on asthma – Google News